Osmotica Pharmaceuticals (OSMT) Announces 5M Share Proposed Public Offering of Ordinary Shares

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the commencement of a proposed public offering of 5,000,000 ordinary shares. All of the shares will be offered by Osmotica. Osmotica also expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 ordinary shares.

Credit Suisse Securities (USA) LLC will act as sole bookrunner for the proposed offering.

The ordinary shares will be offered and sold pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-236193) filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 31, 2020 and declared effective on February 12, 2020.

You May Also Be Interested In

• AMC Entertainment prices $200M stock offering to redeem senior notes
• XTEND wins $9M Middle East drone contract, adds two patents
• Gorilla Technology signs $2.5B AI compute contract in Indonesia